Older men may not need prostate cancer screening

Key points
- The findings of a new study provide further evidence that screening older men for prostate cancer is not worthwhile and may actually do harm.
- Screening usually picks up localized prostate cancer.
- In the study, reported in the American Journal of Medicine, Dr.
- The 175 men in the aggressive treatment group underwent prostate surgery or radiation therapy.
The findings of a new study provide further evidence that screening older men for prostate cancer is not worthwhile and may actually do harm. Aggressive treatment of prostate cancers detected in patients in this age group has a minimal effect on survival, but markedly impairs quality of life, according to the study.
Screening usually picks up localized prostate cancer. Given the typically slow growth of this malignancy, the conventional wisdom has been that even if untreated, older men with screen-detected disease are more likely to die with prostate cancer rather than from it. This point, coupled with the risks of aggressive prostate cancer treatment, has led many to question the value of screening in older men.
In the study, reported in the American Journal of Medicine, Dr. Richard M. Hoffman, from the New Mexico VA Health Care System, and colleagues assessed the outcomes of 465 men, between 75 and 84 years of age, who underwent aggressive or conservative treatment for localized prostate cancer.
The 175 men in the aggressive treatment group underwent prostate surgery or radiation therapy. The conservative management group included the remaining 290 patients who received hormone therapy or no treatment.
Aggressive treatment had little impact on the prostate cancer survival rate, the report indicates. The absolute difference in prostate cancer survival over 5 years was similar in both treatment groups. Moreover, in agreement with previous reports, the majority of all deaths - 80 percent - were not due to prostate cancer.
At 2-year follow-up, aggressive treatment was more likely to adversely impact quality of life than was conservative management. Compared with conservatively managed patients, those treated with aggressive therapy were roughly three times more likely to report daily urinary leakage and complain of sexual problems, and five times more likely to be bothered by other urinary problems.
"Most professional organizations, even those that support prostate cancer screening, recommend that we probably shouldn't be screening men who are over 75," Hoffman told Reuters Health.
"Men who were treated aggressively ended up having a lot more sexual and urinary problems" than men treated conservatively, yet experienced little or no survival benefit, he added. "We think this reinforces the notion that screening older men should really be done very cautiously."
Hoffman emphasized that "there is no evidence that prostate cancer screening is of any benefit to older men and we're finding now that there's evidence of harm."
SOURCE: American Journal of Medicine, May 2006.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
NewsCervical cancer vaccines may cut need for screening
Using GlaxoSmithKline's Cervarix vaccine to protect girls against the HPV virus that causes cervical cancer is so effective that health authorities could reduce the need for later cervical screening, scientists said on…
10 November 2011
NewsOlder men get less effective prostate cancer care
Old age is no hindrance to benefiting from prostate cancer surgery and radiation therapy, according to a new U.S. study that shows men over 75 often get less effective treatment than their younger peers. "It seems men…
8 December 2010
NewsProstate cancer screening improves quality of life by catching disease before it spreads
Men treated for prostate cancer who were diagnosed after the start of routine screening had a significantly reduced risk of the disease spreading to other parts of the body (metastases) within 10 years of treatment,…




